The cell banking outsourcing market is expected to cross USD 12.08 Billion by 2032 at a CAGR of 15.9% during the forecast period of 2023 to 2032. An increasing number of cell banks globally is projected to propel the growth of the cell banking outsourcing market size during the forecast period. Increasing number of applications of cell-based products for research as well as the rapies is another factor expected to grow the market size. Moreover, asurge in the number of start-ups focused on cell-based therapies and vaccine production is likely to fuel market growth.
COVID-19 Analysis
The rising prevalenceof COVID-19 is projected to influence market growth over the forecast period. As the coronavirus outbreak continues, the majority of the pharmaceutical companies experienced a significant loss, thereby hampering the cell banking outsourcing market.
Many companies halted their manufacturing and supply operations in the initial phase of the pandemic. However, the current situation of COVID-19 is expected to reach normalcy since the medical professionals and health authorities in the countries are taking the necessary steps to fight against the virus.The European Society for Blood and Marrow Transplantation has recommended waiting at least 21 days before donation for infected donors. In Italy, the National Transplant Centre has recommended testing through real-time RT-PCR assays for tissue and stem cell donors. Several studies worldwide are looking into whether Mesenchymal Stem Cells (MSCs) can aid the treatment of some of the effects COVID-19 can have on the respiratory system.
An article published online dated March 12, 2021, in Blood Research reviewedthe impact of COVID-19 on cord blood banking globally. It analysed the number of unrelated Stem Cell Transplantations (SCTs) using bone marrow or peripheral blood were similar in South Korea in 2019 and 2020.Thus the SCTs donations were not significantly affected by the COVID-19 pandemic in Korea. However, numbers of volunteer adult stem cell donors decreased dramatically for several months after March 2020, compared to 2018 and 2019, and then recovered since July 2020.Similarly, many drugs have been examined in clinical trials, and 10.2% of registered COVID-19 studies used stem cellsand cord blood to try to prevent the progression of COVID-19. An increasing reliance on cell-based therapies for probable COVID-19 treatment is projected to increase the demand for cell banking services such as storage and processing.
In May 2022, Anja Health raised $4.5 million in seed funding to make cord blood stem cell banking accessible for all, regardless of race, socio-economic status or income. The new funding will bring in the strengthening of the company's leadership team, promote strategic growth as well as foster its community.
In April 2022, Pluristyx and Accelerated Biosciences agreed to generate clinical-grade hESC banks under GMP guidelines (GMP) – a biotech firm focused on advanced therapeutic tools and services and the pioneer in regenerative medicine engaged in proprietary human trophoblast stem cells (hTSCs) respectively.
GMP-grade hESC banks were made between Pluristyx, a biotech firm focusing on advanced therapeutics tools and services and Accelerated Biosciences, the leading regenerative medicine pioneer using its own proprietary human trophoblast stem cells (hTSCs).
ATUM initiated Good Manufacturing Practices (cGMP) compliant Master Cell Banking production services from a California-based bioengineering company in April 2022. Such a move enables ATUM to provide end-to-end cell line development that includes DNA designing through the Release of a Master Cell Bank (MCB) and Working Cell Bank (WCB) supporting Investigational New Drug applications.
Rising applications and clinical trials related to stem cells
Market Restraints
High capital investment and ethical issues related to donation of cells
Market Opportunities
Development of cell banks in developing countries
Cell banks helps in characterizations of cell lines.They reduce the cost of cell culture processes by storing and retrieving cell lines whenever required. Similarly, the increasing focus on regenerative and personalized medicine is likely to create an opportunity for the cell banking outsourcing market to grow.Several key players focus on catering products and services to the American and European markets due to well-established healthcare infrastructure, huge patient population, and high healthcare expenditure.No public cord blood banks are present in Africa, and the prohibitive cost of bringing in cord blood units from overseas is not simply feasible for most patients. The launch of subsidiaries in the developing regions can be profitable with first to market advantage.
Value Chain Analysis
The cell banking outsourcing market is projected to exhibit significant growth over the forecast period, which can be attributed to factors such as a rise in the per capita disposable income, rapid technological advancements in the cell banking outsourcing services, and the availability of better medical facilities, along with increasing patient pool in need of cell-based therapies. The value chain analysis for the cell banking outsourcing industry comprises four major components, which start with the research & product development, followed by the manufacturing of the products, distribution, and ends with post marketing surveillance.
Master Cell Bank(MCB) is expected to be the fastest-growing segment during the period of 2021–2027 dueto its need to create Working Cell Bank (WCB). In the process of cell development, cells are extracted from normal, embryonic, and malignant tissues. These cells are propagated in vitro.A master cell bank is produced from the original therapeutic-producing cell line.
WCBis derived from MCB.In order to prevent loss of cell lines from contamination,it is necessary to stored WCB in separate storage areas.The WCB is prepared from cells obtained from culturing the MCB under aseptic conditions.
The creation of a Master Virus Bank ensures reproducible testing and production of recombinant viruses to develop vaccines and recombinant proteins.Viral banking services are completely segregated from non-viral activities to ensure no cross-contamination of products.
The process of gathering, treating, and creating repositoriesof stem cells for future is termed as stem cell banking. The growing application scope of stem cells in therapies and regenerative medicine is anticipated to increase the growth of this segment. Stem cells have the potential to regenerate. This ability to develop into many different types of blood and tissue cell increases its applications in research and therapies.
Non-stem cellsinclude somatic cells preserved for applications such as tissue engineering and Induced Pluripotent Stem Cells (iPSCs) development. Advanced Therapy Medicinal Products (ATMPs) such as TiGenix’s (Belgium) ChondroCelectis used to repair damaged cartilage in the knee.
Cell banks store the biological products at negative temperatures using liquid nitrogen for cryopreservation. Most of the cell banks store MCB and WCB at -70oC to -150oC. Primary site storage facilitiesfor Master Cell Banks are divided and maintained at two different locations.The cell banks store cord blood and stem cells of newborn individuals for future use.
Cells are generally prepared for banking by expanding cultures in a progressively greater number or larger vessel size until a pool of cells can be obtained, which is sufficient to generate enough containers for the bank.This preparation of cell banks is important for pre-clinical research as well as therapy.
The process for characterizing cell lines can be extensive, requiring an array of testing options for specific scenarios. From adventitious agent testing to identity and genetic stability testing, it is important to know availableoptions, time to perform tests, and the impact of testing on the overall project schedule and outcome.Chinese Hamster Ovary (CHO) cells are by far the most used production cell lines in the pharmaceutical industry.
The North Americancell bank outsourcing market held the largest share in 2020 due to the presence of major manufacturers,favorable government regulations, and high healthcare expenditure in the region. The availability of an increasing number of stem cell banks (both public and private) is anticipated to support the market growth globally.
The European cell banking outsourcing market is driven byincreasing government initiatives and the large availability of research grants. The growing geriatric population, predisposition to chronic diseases, and large support for storage of cord blood and stem cells are projected to expand the size of the cell banking outsourcing market in the region.
The cell banking outsourcing market is projected to record at the highest CAGR during the forecast period. This regional market growth is attributed to the rising population, increasing number of patients suffering from chronic diseases such as oncological diseases,and the increasing number of contractual research and development organizations. The clinical trials in the region continue to grow rapidly. Novotech (Australia), a contract research organization, observed biotech clinical activity up by 26% in 2019.Furthermore, in September 2020, Anglo-Swedish pharma firm AstraZeneca teamed with Contract Development and Manufacturing Organization (CDMO) Samsung Biologics (South Korea) in a long-term deal. Samsung Biologics has also announced a plethora of contracts with smaller biopharma firms, including Belgian firm UCB, Cytodyn (US), PharmAbcine (South Korea), Panolos Bioscience (South Korea), Immunomedics (US), ImmuneOncia Therapeutics Inc. (South Korea), and STCube (South Korea).
The rest of the world is segmented into Middle East, Africa, and Latin America. The cell banking outsourcing market in the region is driven bytechnological development, developing healthcare infrastructure, and growing acceptance of advanced therapies.
Competitive Landscape
The cell banking outsourcing market is characterized by the presence of many global, regional, and local vendors catering to the demand created by research scientists and pharmaceutical and biotechnology companies operating in the industry.The growing demand from customers is propelling the cell banking outsourcing market growth.The market is highly competitive, with players competing and partnering to gain a substantial market share. For instance, in February 2021, Catalent (US), a global provider of manufacturing solution for drugs, biologics, cell and gene therapiessigned an agreement with Trizell GmbH (Germany), to support the manufacturing of Trizell’s Phase 1 cell therapy for the treatment of micro- and macroangiopathies.The prominent players are involved in strategic agreements and joint ventures to sustain their market positions.
Recent Developments
Key Players
Report Overview
The study covers the existing short-term and long-term market effect, as well as helping decision-makers to draught short-term and long-term plans for businesses by region. The report covers major regions in North America, Europe, Asia Pacific, and the rest of the world. The report analyzes market drivers, restraints, opportunities, challenges, Porter's Five Forces, Value Chain, and impact of COVID-19 on the market.
Scope of the Report
The scope of the global cell banking outsourcing market study includes market size analysis and a detailed analysis of the manufacturer’s products and strategies. The market has been segmented based on bank type, cell type, application, and region.
| Report Attribute/Metric | Details |
| Â Â Market Size | Â Â 2030: USD 12.08 Billion |
| Â Â CAGR | Â Â 15.9% |
| Â Â Base Year | Â Â 2021 |
| Â Â Forecast Period | Â Â 2023-2032 |
| Â Â Historical Data | Â Â 2020 |
| Â Â Forecast Units | Â Â Value (USD Million) |
| Â Â Report Coverage | Â Â Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Â Â Segments Covered | Â Â Bank Type, Cell Type and Application |
| Â Â Geographies Covered | Â Â North America, Europe, Asia-Pacific, Rest of the World |
|   Key Vendors |  CordLife (Singapore), Cleancells (France), Charles River Laboratories (US), BSL Bioservice (Germany), BioReliance (US), Sartorius (Germany), Covance (US), LifeCell International Pvt. Ltd. (India), Goodwin Biotechnology Inc. (US), GlobalStem Inc. (US), Cryo-Cell International Inc. (US), Lonza (Switzerland), PX’TherapeuticsSA (France), Wuxi Apptec (China), SGS Life Sciences (Switzerland) |
| Â Â Key Market Opportunities | Â Â Development of cell banks in developing countries |
|   Key Market Drivers |   Increasing strategic decisions by key players • Rising applications and clinical trials related to stem cells |
Cell Banking Outsourcing Market Highlights:
Frequently Asked Questions (FAQ) :
Global cell banking outsourcing market is expected to cross USD 12.08 Billion by 2032
Cell Banking Outsourcing Market is expected to register a CAGR of ~15.90% during the forecast period of 2023-2032
Some of the key players in the global cell banking outsourcing marketare CordLife (Singapore), Cleancells (France), Charles River Laboratories (US), BSL Bioservice (Germany), BioReliance (US), Sartorius (Germany), Covance (US), LifeCell International Pvt. Ltd. (India), Goodwin Biotechnology Inc. (US), GlobalStem Inc. (US), Cryo-Cell International Inc. (US), Lonza (Switzerland), PX’TherapeuticsSA (France), Wuxi Apptec (China), SGS Life Sciences (Switzerland), among others.
An increasing number of cell banks globally is projected to propel the growth of the global cell banking outsourcing market size during the forecast period. Increasing number of applications of cell-based products for research as well as the rapies is another factor expected to grow the market size. Moreover, asurge in the number of start-ups focused on cell-based therapies and vaccine production is likely to fuel market growth.
Based on bank type, the market has been divided into master cell banking, working cell banking, and viral cell banking. Master cell banking is likely to hold maximum market share in the global cell banking outsourcing market owing to its larger utility globally.
Cell banking outsourcing market application are cell bank storage, cell bank preparation,and bank characterization & testing.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
